C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment Posted on 26. March 20207. July 2020 by c2p-editor
Andrew Badrot, CEO of C2 PHARMA, weighing in on the future trends of mergers and acquisitions in the life sciences industry Posted on 19. March 20207. July 2020 by c2p-editor
C2 PHARMA Expands Advisory Board to Support Growth Objectives Posted on 3. March 20207. July 2020 by c2p-editor